Reported Earnings • Feb 14
Third quarter 2026 earnings released: ₹0.58 loss per share (vs ₹1.17 loss in 3Q 2025) Third quarter 2026 results: ₹0.58 loss per share (improved from ₹1.17 loss in 3Q 2025). Net loss: ₹865.1k (loss narrowed 51% from 3Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 165 percentage points per year, which is a significant difference in performance. 공시 • Feb 09
Starsource Multitrade Limited to Report Q3, 2026 Results on Feb 12, 2026 Starsource Multitrade Limited announced that they will report Q3, 2026 results on Feb 12, 2026 공시 • Nov 10
Starsource Multitrade Limited to Report Q2, 2026 Results on Nov 13, 2025 Starsource Multitrade Limited announced that they will report Q2, 2026 results on Nov 13, 2025 New Risk • Oct 03
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 8.3% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.3% average weekly change). Earnings have declined by 47% per year over the past 5 years. Revenue is less than US$1m (₹3.4m revenue, or US$38k). Market cap is less than US$10m (₹198.0m market cap, or US$2.23m). New Risk • Sep 01
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 6.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 47% per year over the past 5 years. Revenue is less than US$1m (₹3.4m revenue, or US$38k). Market cap is less than US$10m (₹187.0m market cap, or US$2.12m). Minor Risk Share price has been volatile over the past 3 months (6.6% average weekly change). New Risk • Aug 14
New major risk - Revenue and earnings growth Earnings have declined by 47% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 47% per year over the past 5 years. Revenue is less than US$1m (₹3.4m revenue, or US$39k). Market cap is less than US$10m (₹202.4m market cap, or US$2.31m). 공시 • Aug 13
Chemo Pharma Laboratories Limited, Annual General Meeting, Sep 24, 2025 Chemo Pharma Laboratories Limited, Annual General Meeting, Sep 24, 2025, at 16:00 Indian Standard Time. 공시 • Aug 05
Chemo Pharma Laboratories Limited to Report Q1, 2026 Results on Aug 12, 2025 Chemo Pharma Laboratories Limited announced that they will report Q1, 2026 results on Aug 12, 2025 Valuation Update With 7 Day Price Move • May 26
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to ₹146, the stock trades at a trailing P/E ratio of 56.1x. Average trailing P/E is 26x in the Diversified Financial industry in India. Total returns to shareholders of 306% over the past three years. 공시 • May 14
Chemo Pharma Laboratories Limited to Report Q4, 2025 Results on May 29, 2025 Chemo Pharma Laboratories Limited announced that they will report Q4, 2025 results on May 29, 2025 공시 • Apr 23
Chemo Pharma Laboratories Limited Approves the Appointment of Bhawna Rajput as Company Secretary and Compliance Officer, Effective 16 April, 2025 Chemo Pharma Laboratories Limited announced that at the board meeting held on April 16, 2025, approved the appointment of CS Bhawna Rajput as Company Secretary and Compliance Officer of the Company with effect from 16 April, 2025. Valuation Update With 7 Day Price Move • Feb 12
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to ₹63.05, the stock trades at a trailing P/E ratio of 24.2x. Average trailing P/E is 25x in the Diversified Financial industry in India. Total returns to shareholders of 45% over the past three years. New Risk • Jan 28
New minor risk - Profit margin trend The company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 38% Last year net profit margin: 90% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Revenue is less than US$1m (₹10m revenue, or US$119k). Market cap is less than US$10m (₹127.7m market cap, or US$1.48m). Minor Risk Profit margins are more than 30% lower than last year (38% net profit margin). 공시 • Jan 13
Chemo Pharma Laboratories Limited to Report Q3, 2025 Results on Jan 27, 2025 Chemo Pharma Laboratories Limited announced that they will report Q3, 2025 results on Jan 27, 2025 Valuation Update With 7 Day Price Move • Dec 19
Investor sentiment deteriorates as stock falls 22% After last week's 22% share price decline to ₹98.45, the stock trades at a trailing P/E ratio of 11.9x. Average trailing P/E is 29x in the Diversified Financial industry in India. Total returns to shareholders of 234% over the past three years. Valuation Update With 7 Day Price Move • Dec 04
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to ₹93.82, the stock trades at a trailing P/E ratio of 11.3x. Average trailing P/E is 27x in the Diversified Financial industry in India. Total returns to shareholders of 206% over the past three years. Valuation Update With 7 Day Price Move • Nov 04
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₹82.72, the stock trades at a trailing P/E ratio of 10x. Average trailing P/E is 29x in the Diversified Financial industry in India. Total returns to shareholders of 172% over the past three years. 공시 • Oct 15
Chemo Pharma Laboratories Limited to Report Q2, 2025 Results on Oct 28, 2024 Chemo Pharma Laboratories Limited announced that they will report Q2, 2025 results on Oct 28, 2024 Valuation Update With 7 Day Price Move • Oct 10
Investor sentiment improves as stock rises 31% After last week's 31% share price gain to ₹86.07, the stock trades at a trailing P/E ratio of 12.1x. Average trailing P/E is 28x in the Diversified Financial industry in India. Total returns to shareholders of 246% over the past three years. New Risk • Aug 28
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Revenue is less than US$1m (₹17m revenue, or US$204k). Market cap is less than US$10m (₹107.8m market cap, or US$1.28m). Minor Risk Share price has been volatile over the past 3 months (7.9% average weekly change). Valuation Update With 7 Day Price Move • Aug 28
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₹78.99, the stock trades at a trailing P/E ratio of 11.1x. Average trailing P/E is 27x in the Diversified Financial industry in India. Total returns to shareholders of 220% over the past three years. Valuation Update With 7 Day Price Move • Jul 24
Investor sentiment improves as stock rises 21% After last week's 21% share price gain to ₹72.50, the stock trades at a trailing P/E ratio of 9.1x. Average trailing P/E is 31x in the Diversified Financial industry in India. Total returns to shareholders of 194% over the past three years. Valuation Update With 7 Day Price Move • Jul 10
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to ₹58.00, the stock trades at a trailing P/E ratio of 7.2x. Average trailing P/E is 31x in the Diversified Financial industry in India. Total returns to shareholders of 124% over the past three years. 공시 • May 12
Chemo Pharma Laboratories Limited to Report Q4, 2024 Final Results on May 27, 2024 Chemo Pharma Laboratories Limited announced that they will report Q4, 2024 final results on May 27, 2024 Valuation Update With 7 Day Price Move • Mar 27
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to ₹63.28, the stock trades at a trailing P/E ratio of 7.1x. Average trailing P/E is 24x in the Diversified Financial industry in India. Total returns to shareholders of 255% over the past three years. 공시 • Jan 10
Chemo Pharma Laboratories Limited to Report Q3, 2024 Results on Jan 29, 2024 Chemo Pharma Laboratories Limited announced that they will report Q3, 2024 results on Jan 29, 2024 Valuation Update With 7 Day Price Move • Jan 10
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to ₹75.63, the stock trades at a trailing P/E ratio of 13.7x. Average trailing P/E is 26x in the Diversified Financial industry in India. Total returns to shareholders of 119% over the past three years. Valuation Update With 7 Day Price Move • Dec 19
Investor sentiment improves as stock rises 25% After last week's 25% share price gain to ₹57.37, the stock trades at a trailing P/E ratio of 10.4x. Average trailing P/E is 25x in the Diversified Financial industry in India. Total returns to shareholders of 190% over the past three years. Valuation Update With 7 Day Price Move • Oct 26
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to ₹37.15, the stock trades at a trailing P/E ratio of 6x. Average trailing P/E is 27x in the Diversified Financial industry in India. Total returns to shareholders of 106% over the past three years. Board Change • Sep 02
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Non-Executive Independent Director Nand Pareek was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. New Risk • Aug 09
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Revenue is less than US$1m (₹11m revenue, or US$134k). Market cap is less than US$10m (₹57.5m market cap, or US$693.4k). Minor Risk Share price has been volatile over the past 3 months (7.3% average weekly change). Valuation Update With 7 Day Price Move • Aug 03
Investor sentiment improves as stock rises 28% After last week's 28% share price gain to ₹34.81, the stock trades at a trailing P/E ratio of 5.6x. Average trailing P/E is 26x in the Diversified Financial industry in India. Total returns to shareholders of 404% over the past three years. 공시 • May 26
Chemo Pharma Laboratories Limited Announces Executive Changes Chemo Pharma Laboratories Limited announced at the board meeting held on May 24, 2023 that the company approved Appointment of Unnati Jain, Company Secretary and Compliance Officers of the Company. Ms. Unnatti Jain aged 32 years is a qualified Company Secretary and a Bachelor of Commerce Graduate. She has worked with public and private limited companics as a Company Secretary. She has vast experience in the field of Companies Act, SEBI Rules and Regulation, LODR and related work. Her knowledge and experience in the legal and compliance field will help the company in a significant way. Mr. Ashok Somani as ceased to Compliance Officer of the Company. 공시 • May 17
Chemo Pharma Laboratories Limited to Report Q4, 2023 Results on May 24, 2023 Chemo Pharma Laboratories Limited announced that they will report Q4, 2023 results at 3:30 PM, Indian Standard Time on May 24, 2023 Valuation Update With 7 Day Price Move • Jan 19
Investor sentiment improved over the past week After last week's 16% share price gain to ₹40.00, the stock trades at a trailing P/E ratio of 13.3x. Average trailing P/E is 21x in the Diversified Financial industry in India. Total returns to shareholders of 433% over the past three years. 공시 • Jan 05
Chemo Pharma Laboratories Limited to Report Q3, 2023 Results on Jan 31, 2023 Chemo Pharma Laboratories Limited announced that they will report Q3, 2023 results on Jan 31, 2023 공시 • Dec 27
Chemo Pharma Laboratories Limited Announces Management Changes Chemo Pharma Laboratories Limited informed that the Board of Directors of the Company at their meeting held on December 26, 2022, have discussed and approved the resignation of Ms. Neha Vora as a Company Secretary and Compliance Officer of the Company with effect from December 15, 2022 and approved the appointment of Mr. Ashok Somani, Director as Compliance Officer of the Company with effect from December 26, 2022. 공시 • Dec 16
Chemo Pharma Laboratories Limited Announces Resignation of Neha Vora as Company Secretary / Compliance Officer Chemo Pharma Laboratories Limited informed that Ms. Neha Vora, an Associate Member of the Institute of Company Secretaries of India having membership no.A30747, has resigned from the position of the Company Secretary & Compliance Officer of the Company with effect from end of the office hours on December 15, 2022. Valuation Update With 7 Day Price Move • Nov 30
Investor sentiment improved over the past week After last week's 15% share price gain to ₹41.55, the stock trades at a trailing P/E ratio of 13.8x. Average trailing P/E is 20x in the Diversified Financial industry in India. Total returns to shareholders of 560% over the past three years. 공시 • Oct 14
Chemo Pharma Laboratories Limited to Report Q2, 2023 Results on Oct 20, 2022 Chemo Pharma Laboratories Limited announced that they will report Q2, 2023 results on Oct 20, 2022 Valuation Update With 7 Day Price Move • Jun 29
Investor sentiment improved over the past week After last week's 15% share price gain to ₹38.95, the stock trades at a trailing P/E ratio of 10.4x. Average trailing P/E is 19x in the Diversified Financial industry in India. Total returns to shareholders of 399% over the past three years. Valuation Update With 7 Day Price Move • Jun 29
Investor sentiment improved over the past week After last week's 15% share price gain to ₹38.95, the stock trades at a trailing P/E ratio of 10.4x. Average trailing P/E is 19x in the Diversified Financial industry in India. Total returns to shareholders of 399% over the past three years. 공시 • May 18
Chemo Pharma Laboratories Limited to Report Q4, 2022 Results on May 27, 2022 Chemo Pharma Laboratories Limited announced that they will report Q4, 2022 results on May 27, 2022 Valuation Update With 7 Day Price Move • Jan 03
Investor sentiment improved over the past week After last week's 17% share price gain to ₹34.40, the stock trades at a trailing P/E ratio of 24.7x. Average trailing P/E is 19x in the Diversified Financial industry in India. Total returns to shareholders of 21% over the past three years. Valuation Update With 7 Day Price Move • Apr 20
Investor sentiment improved over the past week After last week's 19% share price gain to ₹23.10, the stock trades at a trailing P/E ratio of 13.9x. Average trailing P/E is 13x in the Diversified Financial industry in India. Total loss to shareholders of 35% over the past three years. 공시 • Jan 12
Chemo Pharma Laboratories Limited to Report Q3, 2021 Results on Jan 28, 2021 Chemo Pharma Laboratories Limited announced that they will report Q3, 2021 results on Jan 28, 2021 Is New 90 Day High Low • Dec 28
New 90-day high: ₹22.80 The company is up 17% from its price of ₹19.43 on 29 September 2020. The Indian market is up 20% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Diversified Financial industry, which is up 26% over the same period. Valuation Update With 7 Day Price Move • Dec 24
Investor sentiment improved over the past week After last week's 15% share price gain to ₹21.75, the stock is trading at a trailing P/E ratio of 12x, up from the previous P/E ratio of 10.5x. This compares to an average P/E of 13x in the Diversified Financial industry in India. Total return to shareholders over the past three years is a loss of 49%. Valuation Update With 7 Day Price Move • Dec 10
Market bids up stock over the past week After last week's 17% share price gain to ₹16.95, the stock is trading at a trailing P/E ratio of 9.4x, up from the previous P/E ratio of 8x. This compares to an average P/E of 13x in the Diversified Financial industry in India. Total return to shareholders over the past three years is a loss of 62%. 공시 • Oct 10
Chemo Pharma Laboratories Limited to Report Q2, 2021 Results on Oct 19, 2020 Chemo Pharma Laboratories Limited announced that they will report Q2, 2021 results on Oct 19, 2020 Is New 90 Day High Low • Sep 24
New 90-day high: ₹17.97 The company is up 165% from its price of ₹6.78 on 16 June 2020. The Indian market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Diversified Financial industry, which is down 4.0% over the same period. 공시 • Aug 11
Chemo Pharma Laboratories Limited to Report Q1, 2021 Results on Aug 18, 2020 Chemo Pharma Laboratories Limited announced that they will report Q1, 2021 results on Aug 18, 2020 공시 • Jun 17
Chemo Pharma Laboratories Limited to Report Q4, 2020 Results on Jun 26, 2020 Chemo Pharma Laboratories Limited announced that they will report Q4, 2020 results on Jun 26, 2020